硬化性移植物抗宿主病与硬皮病共享失调基因表达,抗EREG治疗性抗体可改善该表达
研究开发了全人源抗EREG中和抗体,在人EREG敲入小鼠中验证其功能与安全性。单细胞转录组显示SSc、局限性硬皮病和硬化性GVHD皮肤EREG表达均升高,EREG驱动肌成纤维细胞产生TNC。抗EREG抗体处理活动性SclGVHD皮肤外植体后,空间转录组显示基质降解上调,蛋白检测显示TNC、CCL2、TIMP1分泌减少。
要点
- SSc、局限性硬皮病和硬化性GVHD皮肤中EREG表达均升高,EREG驱动肌成纤维细胞产生TNC。
- 抗EREG治疗性抗体在人EREG敲入小鼠体内显示功能且安全。
- 抗EREG抗体处理活动性SclGVHD皮肤外植体后,TNC、CCL2、TIMP1分泌减少。
核心结论
- 硬化性皮肤经抗EREG治疗性抗体处理后,减少了与EGFR和TLR4信号相关的炎症和纤维化生物标志物。
研究设计与样本
- 研究开发了全人源抗EREG中和抗体,并在人EREG敲入小鼠中体内验证其功能与安全性。
- 对SSc、局限性硬皮病和硬化性GVHD皮肤单细胞转录组图谱与疾病生物标志物进行比对分析。
- 用空间转录组学检测抗EREG治疗性抗体处理的活动性SclGVHD患者皮肤外植体。
主要发现
- 3种纤维化疾病皮肤中EREG表达均升高,EREG是肌成纤维细胞产生TNC的驱动因素。
- TNC作为内源性TLR4配体,诱导TLR4靶基因CCL2和白细胞介素-6表达。
- 抗EREG抗体处理的活动性SclGVHD皮肤外植体空间转录组显示MMP增加、TIMP1表达降低,基质降解上调。
- 蛋白检测显示所有患者EREG靶标TNC、CCL2和TIMP1分泌减少,四分之三患者I型胶原和FN1减少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-driven fibrotic skin diseases, including scleroderma/systemic sclerosis (SSc) and chronic graft-versus-host disease (GVHD), cause skin stiffening that has a major impact on patient quality of life and associated patient mortality. Therapies to improve sclerotic skin resulting from these diseases are largely ineffective. We previously showed that epiregulin (EREG), a dendritic cell type 3-derived epidermal growth factor receptor (EGFR) ligand, is elevated in the skin and lungs of patients with SSc and required for the maintenance of skin fibrosis. Here, we developed a fully human anti-EREG neutralizing antibody that has both high affinity and specificity. We found this therapeutic antibody to be functional and safe in vivo using human EREG knockin mice. To understand the antifibrotic mechanism of targeting EREG, we aligned skin single-cell transcriptomic profiles of SSc, morphea (localized scleroderma), and sclerotic GVHD (SclGVHD) with disease biomarkers. EREG expression in the skin was elevated in all 3 fibrotic diseases and is a driver of tenascin C (TNC) production by myofibroblasts. TNC is a proinflammatory extracellular glycoprotein that functions as an endogenous Toll-like receptor 4 (TLR4) ligand, which induces expression of TLR4 target genes CCL2 and interleukin-6. Examination of skin explants from patients with active SclGVHD treated with anti-EREG therapeutic antibody by spatial transcriptomics demonstrated upregulation of matrix degradation by increased MMP and decreased TIMP1 expression. Protein measurements showed reduced secretion of EREG targets TNC, CCL2, and TIMP1 in all patients and type I collagen and FN1 in three-fourths of patients. Thus, sclerotic skin treated with the anti-EREG therapeutic antibody reduced inflammatory and fibrosis biomarkers associated with EGFR and TLR4 signaling.
引用
- Newton NM, Agrawal K, Odell AV, et al. Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody. Blood. 2025. PMID: 40961242. doi:10.1182/blood.2025029836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。